Daniel J. Starks - Apr 28, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Director
Signature
/s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Apr 28, 2023
Transactions value $
-$5,551,193
Form type
4
Date filed
5/2/2023, 08:04 PM
Previous filing
Oct 31, 2022
Next filing
Jul 28, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +1.82K +0.03% $0.00 6.88M Apr 28, 2023 Direct F1
transaction ABT Common shares without par value Sale -$5.17M -46.5K -0.68% $110.97 6.83M May 2, 2023 Direct F2
transaction ABT Common shares without par value Sale -$386K -3.45K -0.05% $111.75 6.83M May 2, 2023 Direct F3
holding ABT Common shares without par value 258 Apr 28, 2023 Alynne Starks 2012 Irrevocable Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +8.14K $0.00 8.14K Apr 28, 2023 Common Shares 8.14K $110.12 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F5 Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The sale transactions disclosed under Table I were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).